Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome.
The influence of weight reduction and female sex hormones on the regulation of lipolysis was investigated in isolated abdominal sc adipocytes from 20 obese hyperandrogenic women with polycystic ovary syndrome (PCOS). Nine PCOS women were reinvestigated after 8-12 weeks of weight reduction therapy (WR) with a very low calorie diet, inducing a mean loss of 8 +/- 3 kg, and 8 PCOS women were reinvestigated after 12 weeks of treatment with combined oral contraceptives (OC), containing ethinyl estradiol and norethisterone; the remaining 3 subjects were drop-outs. Both WR and OC normalized hyperandrogenicity. WR caused a 50% reduction of basal lipolysis rate and a 5- to 7-fold increased noradrenaline and terbutaline sensitivity (P < 0.02); the latter could be ascribed to a 2-fold increased beta2-adrenoceptor density (P < 0.02) as determined with radioligand binding. There was no change with regard to dobutamine (beta1-adrenoceptor sensitivity) or clonidine, (alpha2-adrenoceptor sensitivity) or to beta1-adrenoceptor density. OC treatment did not influence the basal lipolysis rate or beta2- or alpha2-adrenoceptor sensitivity, but lowered the beta1-adrenoceptor sensitivity 7-fold (P < 0.03) without a reduction in beta1-adrenoceptor density. The OC treatment effect was not observed when forskolin and dibutyryl cAMP, acting on adenylate cyclase or protein kinase A, respectively, were used, suggesting a partial uncoupling of beta1-adrenoceptors. WR therapy, but not OC therapy, caused, in addition to changes in lipolysis function, improved in vivo insulin sensitivity and lower plasma noradrenaline levels. These findings suggest that factors other than hyperandrogenicity modulate lipolysis regulation in obese subjects with PCOS. Disturbances in sympathetic pathways could be of pathogenic importance.
Wahrenberg
H
H
Department of Medicine, Research Center, Huddinge University Hospital, Karolinska Institute, Sweden.
Ek
I
I
Reynisdottir
S
S
Carlström
K
K
Bergqvist
A
A
Arner
P
P
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000273:Adipose Tissue / Q000187:drug effects / Q000473:pathology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology*; D003279:Contraceptives, Oral, Sequential / Q000494:pharmacology; D004038:Diet, Reducing; D045166:Estradiol Congeners / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D008066:Lipolysis / Q000187:drug effects; D009640:Norethindrone / Q000494:pharmacology; D009765:Obesity / Q000178:diet therapy / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000378:metabolism* / Q000503:physiopathology; D011869:Radioligand Assay; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D015431:Weight Loss
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D003277:Contraceptives, Oral, Combined; D003279:Contraceptives, Oral, Sequential; D045166:Estradiol Congeners; D004967:Estrogens; D004997:Ethinyl Estradiol; D009640:Norethindrone